Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab

American Journal of Transplantation

Volumn 10, Issue 8, 2010, Pages 1870-1880

  Posselt, A M ^a   Bellin, M D ^b   Tavakol, M ^a   Szot, G L ^a   Frassetto, L A ^a   Masharani, U ^a   Kerlan, R K ^a   Fong, L ^a   Vincenti, F G ^a   Hering, B J ^b   Bluestone, J A ^a   Stock, P G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Clinical islet transplantation; immunoregulatory T lymphocytes; immunosuppressant therapy; lymphocyte trafficking; prednisone free immunosuppression; type 1 diabetes mellitus

Indexed keywords

BASILIXIMAB; C PEPTIDE; EFALIZUMAB; HEMOGLOBIN A1C; IMMUNOSUPPRESSIVE AGENT; INSULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; BACKACHE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; FATIGUE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; GRAFT REJECTION; HUMAN; HUMAN CELL; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE ERYTHEMA; INJECTION SITE RASH; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; LOW DRUG DOSE; MALE; MOUTH ULCER; NAUSEA; NEUTROPENIA; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; IMMUNOSUPPRESSION; ISLETS OF LANGERHANS TRANSPLANTATION; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SIROLIMUS; TACROLIMUS;

EID: 77954892240     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03073.x     Document Type: Article

References (53)

1. Nathan DM. Long-term complications of diabetes-mellitus N Engl J Med 1993 328 : 1676 1685.
2. Shamoon H, Duffy H, Fleischer N et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes-mellitus. N Engl J Med 1993 329 : 977 986.
3. Shannon H, Duffy H, Dahms W et al. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000 342 : 381 389.
4. Singh RP, Stratta RJ. Advances in immunosuppression for pancreas transplantation. Curr Opin Organ Transpl 2008 13 : 79 84.
5. Sutherland DER, Gruessner AC, Gruessner RWG. Pancreas transplantation: A review. Transpl Proc 1998 30 : 1940 1943.
6. Sutherland DER, Gruessner RWG, Humar A et al. Pretransplant immunosuppression for pancreas transplants alone in nonuremic diabetic recipients. Transpl Proc 2001 33 : 1656 1658.
7. Sutherland DER, Gruessner RWG, Dunn DL et al. Lessons learned from more than 1000 pancreas transplants at a single institution. Ann Surg 2001 233 : 463 501.
8. Sutherland DER, Gruessner RWG, Najarian JS, Gruessner AC. Solitary pancreas transplants: A new era. Transpl Proc 1998 30 : 280 281.
9. Gruessner RW, Sutherland DE, Najarian JS, Dunn DL, Gruessner AC. Solitary pancreas transplantation for nonuremic patients with labile insulin-dependent diabetes mellitus. Transplantation 1997 64 : 1572 1577.
10. Shapiro AMJ, Lakey JRT, Ryan EA et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000 343 : 230 238.
11. Ricordi C, Hering BJ, Shapiro AMJ, Transplantation CI. Beta-cell transplantation for diabetes therapy. Lancet 2008 372 : 27 28.
12. Gruessner RW, Sutherland DE, Parr E, Humar A, Gruessner AC. A prospective, randomized, open-label study of steroid withdrawal in pancreas transplantation-a preliminary report with 6-month follow-up. Transplant Proc 2001 33 : 1663 1664.
13. Naesens M., Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009 4 : 481 508.
14. Nicolls MR, Gill RG. LFA-1 (CD11a) as a therapeutic target. Am J Transplant 2006 6 : 27 36.
15. Corbascio M, Ekstrand H, Osterholm C et al. CTLA4Ig combined with anti-LFA-1 prolongs cardiac allograft survival indefinitely. Transpl Immunol 2002 10 : 55 61.
16. Vincenti F, Mendez R, Pescovitz M et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 2007 7 : 1770 1777.
17. Frampton JE, Plosker GL. Efalizumab: A review of its use in the management of chronic moderate-to-severe plaque psoriasis. Am J Clin Dermatol 2009 10 : 51 72.
18. Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW. Automated method for isolation of human pancreatic islets. Diabetes 1988 37 : 413 420.
19. Bucher P, Mathe Z, Bosco D et al. Serva collagenase NB1: A new enzyme preparation for human islet isolation. Transpl Proc 2004 36 : 1143 1144.
20. Brandhorst H, Friberg A, Andersson HH et al. The importance of tryptic-like activity in purified enzyme blends for efficient islet isolation. Transplantation 2009 87 : 370 375.
21. Szot GL, Lee MR, Tavakol MM et al. Successful clinical islet isolation using a GMP-Manufactured Collagenase and Neutral Protease. Transplantation 2009 88 : 753 756.
22. Owen RJ, Ryan EA, O'Kelly K et al. Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: Radiologic aspects. Radiology 2003 229 : 165 170.
23. Faradji RN, Monroy K, Messinger S et al. Simple measures to monitor beta-cell mass and assess islet graft dysfunction. Am J Transplant 2007 7 : 303 308.
24. Paty BW, Senior PA, Lakey JR, Shapiro AM, Ryan EA. Assessment of glycemic control after islet transplantation using the continuous glucose monitor in insulin-independent versus insulin-requiring type 1 diabetes subjects. Diabetes Technol Ther 2006 8 : 165 173.
25. Brandstrom E, Grzegorczyk A, Jacobsson L et al. GFR measurement with iohexol and 51Cr-EDTA. A comparison of the two favoured GFR markers in Europe. Nephrol Dial Transplant 1998 13 : 1176 1182.
26. Polkinghorne KR. Detection and measurement of urinary protein. Curr Opin Nephrol Hypertens 2006 15 : 625 630.
27. Leischner MP, Naratadam GO, Hou SH, Singh AK, Leehey DJ. Evaluation of proteinuria in healthy living kidney donor candidates. Transplant Proc 2006 38 : 2796 2797.
28. Grant J, Bourcier K, Wallace S et al. Validated protocol for FoxP3 reveals increased expression in type 1 diabetes patients. Cytometry B Clin Cytom 2009 76 : 69 78.
29. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010 61 : 35 47.
30. Korman BD, Tyler KL, Korman NJ. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: A cautionary tale for dermatologists. Arch Dermatol 2009 145 : 937 942.
31. Carson KR, Focosi D, Major EO et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: A Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009 10 : 816 824.
32. Pugashetti R Koo J. Efalizumab discontinuation: A practical strategy. J Dermatolog Treat 2009 20 : 132 136.
33. Shapiro AMJ, Ricordi C, Hering BJ et al. International trial of the edmonton protocol for islet transplantation. N Engl J Med 2006 355 : 1318 1330.
34. Zeng YJ, Ricordi C, Lendoire J et al. The effect of Prednisone on pancreatic-islet autografts in dogs. Surgery 1993 113 : 98 102.
35. Kaufman DB, Baker MS, Chen XJ, Leventhal JR, Stuart FP. Sequential kidney/islet transplantation using prednisone-free immunosuppression. Am J Transpl 2002 2 : 674 677.
36. Drachenberg CB, Klassen DK, Weir MR et al. Islet cell damage associated with tacrolimus and cyclosporine: Morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999 68 : 396 402.
37. Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005 353 : 770 781.
38. Venetz JP Pascual M. New treatments for acute humoral rejection of kidney allografts. Expert Opin Investig Drugs 2007 16 : 625 633.
39. Scheinfeld N. Efalizumab: A review of events reported during clinical trials and side effects. Expert Opin Drug Saf 2006 5 : 197 209.
40. Ramirez E, Morales JM, Lora D et al. Peripheral blood regulatory T cells in long-term kidney transplant recipients. Transplant Proc 2009 41 : 2360 2362.
41. Boros P Bromberg JS. Human FOXP3 +regulatory T cells in transplantation. Am J Transplant 2009 9 : 1719 1724.
42. Kim SH, Oh EJ, Ghee JY et al. Clinical significance of monitoring circulating CD4+CD25+ regulatory T cells in kidney transplantation during the early posttransplant period. J Korean Med Sci 2009 24 (Suppl S135 S142.
43. Adams AB, Shirasugi N, Durham MM et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 2002 51 : 265 270.
44. Joshi A, Bauer R, Kuebler P et al. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: A monoclonal antibody approved for use in psoriasis. J Clin Pharmacol 2006 46 : 10 20.
45. Available at : http://www.gene.com/gene/products/information/pdf/raptiva- prescribing.pdf.
46. Neff RT, Hurst FP, Falta EM et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 2008 86 : 1474 1478.
47. Morgenstern LB Pardo CA. Progressive multifocal leukoencephalopathy complicating treatment for Wegener's granulomatosis. J Rheumatol 1995 22 : 1593 1595.
48. Piccinni C, Sacripanti C, Poluzzi E et al. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. Eur J Clin Pharmacol 2009.
49. Hering BJ, Kandaswamy R, Ansite JD et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005 293 : 830 835.
50. Bromberg JS, Kaplan B, Halloran PF, Robertson RP. The islet transplant experiment: Time for a reassessment. Am J Transpl 2007 7 : 2217 2218.
51. Campbell PM, Senior PA, Salam A et al. High risk of sensitization after failed islet transplantation. Am J Transpl 2007 7 : 2311 2317.
52. Guo T Hebrok M. Stem cells to pancreatic beta-cells: New sources for diabetes cell therapy. Endocr Rev 2009 30 : 214 227.
53. Liew CG Andrews PW. Stem cell therapy to treat diabetes mellitus. Rev Diabet Stud 2008 5 : 203 219.